Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Phase 1 Withdrawn Ossium Health, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Multicenter single arm study to assess the safety and efficacy of allogeneic transplantation using cryopreserved bone marrow from deceased MMUD and PTCy, sirolimus and MMF for GVHD prophylaxis.

Timeline

Start: 2022-09
Primary completion: 2024-03
Completion: 2024-11

Publications

Johnstone BH, Woods JR, Goebel WS, Gu D, Lin CH, Miller HM, Musall KG, Sherry AM, Bailey BJ, Sims E, Sinn AL, Pollok KE, Spellman S, Auletta JJ, Woods EJ. Characterization and Function of Cryopreserved Bone Marrow from Deceased Organ Donors: A Potential Viable Alternative Graft Source. Transplant Cell Ther. 2023 Feb;29(2):95.e1-95.e10. doi: 10.1016/j.jtct.2022.11.010. Epub 2022 Nov 17.

Drugs

Evaluation	Drug	Modality	Dose	Route
Background	2-MERCAPTOETHANESULFONIC ACID	Small molecule	—	—
Background	Busulfan	Small molecule	—	—
Background	Cyclophosphamide	Other / unclassified	—	—
Background	Fludarabine	Small molecule	—	—
Background	Mycophenolate Mofetil	Small molecule	—	—
Background	Sirolimus	Small molecule	—	—
Background	filgrastim	Protein / enzyme biologic	—	—

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Summary

Timeline

Publications

Drugs

Indications